|Bid||34.47 x 1200|
|Ask||34.43 x 3200|
|Day's Range||33.96 - 34.55|
|52 Week Range||26.45 - 43.08|
|Beta (5Y Monthly)||0.62|
|PE Ratio (TTM)||20.15|
|Forward Dividend & Yield||1.56 (4.54%)|
|Ex-Dividend Date||Jan 28, 2021|
|1y Target Est||N/A|
The world grapples with the expected tug-of-war between wealthy and poorer nations over vaccine supplies, paving the way for U.S. adversaries.
The B1351 coronavirus variant from South Africa poses a threat to the currently authorized vaccines from Moderna (NASDAQ: MRNA) and BioNTech (NASDAQ: BNTX)/Pfizer (NYSE: PFE) because they weren't specifically designed to protect against that variant. In this video from Motley Fool Live, recorded on Feb. 22, Fool.com contributors Brian Orelli and Keith Speights discuss the ins and outs of the vaccines' potential to protect against the variants and what the companies are doing to deal with the new challenge. Brian Orelli: We got some data last week published in the New England Journal of Medicine on the coronavirus vaccines protecting against the South African variant -- that's the B1351 -- by Pfizer and BioNTech vaccine, the neutralization was weaker by about two-thirds.
A Russian intelligence agency and Chinese spies were behind cyberattacks on the European Medicines Agency (EMA) last year, Dutch newspaper De Volkskrant reported, citing sources close to the investigation into the breach. The Amsterdam-based European drug regulator in December reported a cyberattack in which documents relating to COVID-19 vaccines and medicines were stolen and leaked on the internet. The Russian foreign ministry did not immediately reply to a request for comment on Saturday, but Moscow has repeatedly denied western allegations of hacking.